SAINT HELIER (dpa-AFX) - Acadia Healthcare Co. Inc. (ACHC) on Friday purchased Delta Medical Center, a 243-bed hospital in Memphis, TN, with the majority of operating beds dedicated to acute inpatient psychiatric patients. This is the second purchase for the year, and the company noted that it will continue to evaluate additional transactions in the fragmented and underserved inpatient psychiatric market.
ACHC closed Friday's trading at $25.89, up 1.25%.
EDAP TMS SA (EDAP) rose more than 17% on Friday following news of submission of its Pre-Market Approval application of Ablatherm-HIFU, a minimally-invasive prostate cancer treatment, to the FDA.
The company's PMA submission includes data from a study, dubbed ENLIGHT, which is a multi-center phase II/III clinical trial, testing Ablatherm-HIFU, as well as data from its extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer.
Hyperion Therapeutics Inc. (HPTX) set a new high of $16.48 in intraday trading on Friday before closing at $16.01, following FDA approval of Ravicti for urea cycle disorders. Ravicti, which is Hyperion's first product, is expected to be commercially available by the end of April 2013.
Perrigo Co. (PRGO) on Friday agreed to acquire OTC companion animal health company, Velcera Inc., for $160 million. The acquisition, which brings in branded veterinary products like PetArmor, is expected to accelerate Perrigo's store brand strategy in the increasingly important OTC adjacent category of retail pet healthcare.
PRGO closed Friday's trading 4.75% higher at $105.28.
Seattle Genetics Inc.'s (SGEN) ADCETRIS on Friday was granted conditional marketing authorization in Canada for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
The drug, which is jointly developed by Seattle Genetics and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd, received accelerated approval from the FDA in August 2011 and was granted conditional marketing authorization by the European Commission in October 2012.
Shire plc (SHPG) on Friday reached an agreement with the U.S. government to resolve the previously disclosed civil investigation looking into promotion of its three ADHD drugs - ADDERALL XR, VYVANSE and DAYTRANA. The agreement also addresses sales and marketing practices relating to LIALDA and PENTASA pursuant to a subsequent voluntary disclosure made by Shire. As a result of the settlement of the inquiry, the company has recorded a charge of $57.5 million in the fourth quarter of 2012.
Supernus Pharmaceuticals Inc. (SUPN) on Friday commercially launched its antiepileptic drug Oxtellar XR tablets in the U.S. Oxtellar XR, a novel once-daily extended release formulation of oxcarbazepine, was approved by the FDA for epilepsy last October.
SUPN closed Friday's trading at $7.76, up 1.17%.
Zoetis Inc. (ZTS), a spinoff of Pfizer Inc.'s animal health unit, which made its debut on the NYSE on Friday, climbed 20% in its first day of trading to close at $31.01.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX